Literature DB >> 33201057

Pediatric Use of Recombinant Human Nerve Growth Factor 20 μg/mL Eye Drops (Cenegermin) for Bilateral Neurotrophic Keratopathy in Congenital Corneal Anesthesia.

Marco G Leto1, Maria E Toro1, Patricia E Indemini1, Claudia Fruttero2, Marco Denina3, Cristina Dalmazzo4, Andrea Sannia4, Agostino S Vaiano1.   

Abstract

PURPOSE: This study aimed to present the efficacy and safety of cenegermin eye drop (Oxervate; Dompè Farmaceutici, Milan, Italy) treatment in a pediatric patient affected by neurotrophic keratopathy (NK) with Goldenhar syndrome.
METHODS: This case reports an infant presenting ulceration and a small central opacity in the cornea of the right and left eyes, respectively. The NK bilaterally worsened despite the use of therapeutic contact lenses and temporary partial tarsorrhaphy. Magnetic resonance imaging showed absence and hypoplasia of the right and left trigeminal nerves, respectively. Cenegermin eye drops were administered 1 drop/each eye, 6 times daily for 8 weeks to promote corneal healing.
RESULTS: Complete healing was achieved in both eyes after treatment. During the 16-month follow-up period, no epithelial defect, recurrence, or complications were noticed, whereas corneal opacities progressively became clearer, although insignificant improvements in corneal sensitivity or in the reflex tearing were observed.
CONCLUSIONS: Cenegermin was effective in treating NK in an infant with Goldenhar syndrome.
Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.

Entities:  

Year:  2021        PMID: 33201057     DOI: 10.1097/ICO.0000000000002612

Source DB:  PubMed          Journal:  Cornea        ISSN: 0277-3740            Impact factor:   2.651


  3 in total

1.  Neurotrophic Keratitis Due to Congenital Corneal Anesthesia with Deafness, Hypotonia, Intellectual Disability, Face Abnormality and Metabolic Disorder: A New Syndrome?

Authors:  Arvydas Gelzinis; Dovile Simonaviciute; Agne Krucaite; Luca Buzzonetti; Hélène Dollfus; Reda Zemaitiene
Journal:  Medicina (Kaunas)       Date:  2022-05-13       Impact factor: 2.948

2.  Maternal serum eye drops to treat bilateral neurotrophic keratopathy in congenital corneal anesthesia: Case report and literature review.

Authors:  Giuseppe Giannaccare; Andrea Lucisano; Marco Pellegrini; Gianfranco Scuteri; Alessandra Mancini; Cristina Malaventura; Massimo Busin; Vincenzo Scorcia
Journal:  Am J Ophthalmol Case Rep       Date:  2022-02-18

3.  Neurotrophic Keratopathy Treated with Topical Recombinant Human Nerve Growth Factor (Cenegermin): Case Series Study with Long-Term Follow-Up.

Authors:  Salvador García-Delpech; Patricia Udaondo; Alex Samir Fernández-Santodomingo; Damian García-Teillard
Journal:  Case Rep Ophthalmol       Date:  2022-08-31
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.